IBDEI0N5 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11386,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,11387,0)
 ;;=200.30^^76^748^31
 ;;^UTILITY(U,$J,358.3,11387,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11387,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,11387,1,2,0)
 ;;=2^LYMPHOMA,MARGINAL ZONE
 ;;^UTILITY(U,$J,358.3,11387,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,11388,0)
 ;;=200.50^^76^748^33
 ;;^UTILITY(U,$J,358.3,11388,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11388,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,11388,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS
 ;;^UTILITY(U,$J,358.3,11388,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,11389,0)
 ;;=202.90^^76^748^32
 ;;^UTILITY(U,$J,358.3,11389,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11389,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,11389,1,2,0)
 ;;=2^LYMPHOMA,OTHER SITE
 ;;^UTILITY(U,$J,358.3,11389,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,11390,0)
 ;;=200.10^^76^748^34
 ;;^UTILITY(U,$J,358.3,11390,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11390,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,11390,1,2,0)
 ;;=2^LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,11390,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11391,0)
 ;;=172.9^^76^748^35
 ;;^UTILITY(U,$J,358.3,11391,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11391,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,11391,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,11391,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,11392,0)
 ;;=199.0^^76^748^37
 ;;^UTILITY(U,$J,358.3,11392,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11392,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,11392,1,2,0)
 ;;=2^METASTATIC CA OF UNKN PRIMARY
 ;;^UTILITY(U,$J,358.3,11392,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,11393,0)
 ;;=203.00^^76^748^38
 ;;^UTILITY(U,$J,358.3,11393,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11393,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,11393,1,2,0)
 ;;=2^MULTIPLE MYELOMA
 ;;^UTILITY(U,$J,358.3,11393,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,11394,0)
 ;;=238.75^^76^748^39
 ;;^UTILITY(U,$J,358.3,11394,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11394,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,11394,1,2,0)
 ;;=2^MYELODYSPLASTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,11394,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,11395,0)
 ;;=157.9^^76^748^41
 ;;^UTILITY(U,$J,358.3,11395,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11395,1,1,0)
 ;;=1^157.9
 ;;^UTILITY(U,$J,358.3,11395,1,2,0)
 ;;=2^PANCREATIC CANCER
 ;;^UTILITY(U,$J,358.3,11395,2)
 ;;=^267103
 ;;^UTILITY(U,$J,358.3,11396,0)
 ;;=187.9^^76^748^42
 ;;^UTILITY(U,$J,358.3,11396,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11396,1,1,0)
 ;;=1^187.9
 ;;^UTILITY(U,$J,358.3,11396,1,2,0)
 ;;=2^PENILE CANCER
 ;;^UTILITY(U,$J,358.3,11396,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,11397,0)
 ;;=163.9^^76^748^44
 ;;^UTILITY(U,$J,358.3,11397,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11397,1,1,0)
 ;;=1^163.9
 ;;^UTILITY(U,$J,358.3,11397,1,2,0)
 ;;=2^PLEURAL CANCER
 ;;^UTILITY(U,$J,358.3,11397,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,11398,0)
 ;;=185.^^76^748^45
 ;;^UTILITY(U,$J,358.3,11398,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11398,1,1,0)
 ;;=1^185.
 ;;^UTILITY(U,$J,358.3,11398,1,2,0)
 ;;=2^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,11398,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,11399,0)
 ;;=287.9^^76^748^46
 ;;^UTILITY(U,$J,358.3,11399,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11399,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,11399,1,2,0)
 ;;=2^PURPURA/OTH HEMORRHAGIC COND
 ;;^UTILITY(U,$J,358.3,11399,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,11400,0)
 ;;=154.3^^76^748^47
 ;;^UTILITY(U,$J,358.3,11400,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11400,1,1,0)
 ;;=1^154.3
